Acorda Raises More PIPE

Paul Capital Healthcare (f.k.a. Paul Royalty Fund) has committed up to $10 million in additional capital to Acorda Therapeutics (Nasdaq: ACOR). The tranched-out deal includes $5 million at closing and the potential for an additional $5 million if it achieves a 2006 sales milestone. Paul Capital previously had invested $15 million, in order to fund salesforce expansion.< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />